Concepedia

Author

Ivo Veletić

The University of Texas MD Anderson Cancer CenterORCID

Also Known As

Ivo Veletic, Ivo Veletić

61

Publications

382

Citations

11

H-Index

34

Concepts

All Affiliations

The University of Texas MD Anderson Cancer CenterTel Aviv UniversityRabin Medical CenterBrigham and Women's HospitalMassachusetts General Hospital
IV

About

Ivo Veletić is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, hematology, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

138

2

Cell Biology

3

3

81

3

Immunology

3

3

81

4

Health Sciences

1

1

20

5

Medical Laboratory Science

1

1

37

Ivo Veletić

×

13

Publications

345

Citations

11

H-Index

YearCitations

Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies

Bofei Wang, Patrick K. Reville, Mhd Yousuf Yassouf,

Nature Communications

2024

57

Activation of the B‐cell receptor successively activates NF‐κB and STAT3 in chronic lymphocytic leukemia cells

Uri Rozovski, David Harris, Ping Li,

International Journal of Cancer

2017

54

PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study

Srđan Verstovšek, Robert P. Hasserjian, Olga Pozdnyakova,

Blood

2018

47

Assessing serum albumin concentration, lymphocyte count and prognostic nutritional index might improve prognostication in patients with myelofibrosis

Marko Lucijanić, Ivo Veletić, Dario Rahelić,

Wiener klinische Wochenschrift

2018

37

Constitutive Phosphorylation of STAT3 by the CK2–BLNK–CD5 Complex

Uri Rozovski, David Harris, Ping Li,

Molecular Cancer Research

2017

25

Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial

Preetesh Jain, Michael J. Keating, Sarah Renner,

The Lancet Haematology

2017

20

Myelofibrosis osteoclasts are clonal and functionally impaired

Ivo Veletić, Taghi Manshouri, Asha S. Multani,

Blood

2019

20

GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes

Taghi Manshouri, Ivo Veletić, Ping Li,

Cell Death and Disease

2022

20

Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis

Ivo Veletić, Sanja Prijić, Taghi Manshouri,

Haematologica

2020

17

Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial

Srđan Verstovšek, Lynda Foltz, Vikas Gupta,

Haematologica

2023

17

Page 1